Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

NCT02269579 ·Status: WITHDRAWN ·Phase: PHASE2

Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT04402541 ·Status: COMPLETED ·Phase: PHASE1

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

NCT01422486 ·Status: TERMINATED ·Phase: PHASE2

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

NCT00761449 ·Status: COMPLETED ·Phase: PHASE2

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

NCT00624585 ·Status: COMPLETED ·Phase: NA

Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

NCT01459159 ·Status: TERMINATED ·Phase: PHASE2

Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT01795924 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

NCT05168904 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

NCT00424229 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867 ·Status: RECRUITING ·Phase: PHASE2

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

NCT00910858 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

NCT00255346 ·Status: COMPLETED ·Phase: PHASE2

Erlotinib Study for Myelodysplastic Syndrome (MDS)

NCT00977548 ·Status: COMPLETED ·Phase: PHASE2

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01804101 ·Status: COMPLETED ·Phase: NA

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT01433965 ·Status: COMPLETED ·Phase: PHASE1

A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

NCT06294275 ·Status: COMPLETED ·Phase: PHASE1

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

NCT05319587 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study

NCT03335943 ·Status: UNKNOWN ·Phase: PHASE4

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT05143996 ·Status: RECRUITING ·Phase: PHASE1

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

NCT03359460 ·Status: COMPLETED ·Phase: PHASE1

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

NCT00109538 ·Status: TERMINATED ·Phase: PHASE3

CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.

NCT04109690 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

NCT01497145 ·Status: COMPLETED ·Phase: PHASE2

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

NCT00005845 ·Status: COMPLETED ·Phase: PHASE1

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

NCT00502112 ·Status: COMPLETED ·Phase: PHASE1